Remove Protein Expression Remove RNA Remove Science
article thumbnail

Building Korro Bio: A CEO’s Perspective on Innovation and Risk Management

LifeSciVC

Founding Vision: Harnessing RNA Editing for Transformative Medicine Korro Bio’s story began in 2018, co-founded by a remarkable group: Jean-François Formela, M.D. Academic specializing in RNA editing). Their collective expertise—spanning gene editing, venture creation, and foundational science—set the stage for building Korro.

RNA 67
article thumbnail

The Magic of Fast Feedback Loops

Codon

One such opportunity, for example, is in protein expression. When working with proteins — or designing new ones — scientists must first express them within a cellular “host,” which in turn demands that the proteins be successfully translated and folded into a stable, soluble structure.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Protein Science & Structural Biology

Sygnature Discovery

We’ve successfully tackled targets for: Unprecedented membrane proteins Intrinsically disordered proteins Refolding from inclusion bodies Large protein complexes Labelled proteins for NMR studies RNA structures by crystallography Across our capabilities Protein Expression & Purification Vast diversity of proteins produced.

Science 52
article thumbnail

Accelerating Riboswitch Engineering for the Development of Human Performance Biosensors - A Preview of Strateos’ Presentation at SynBioBeta 2021

The Strateos Blog: Drug Discovery

SynBioBeta is one of synthetic biology’s premier events, bringing together a diverse community of thought leaders, technology innovators, engineers, scientists, and policy makers to explore the exciting new advancements that are shaping the future of science. coli extract-based cell-free protein expression assays.

article thumbnail

Biopharma Money on the Move: December 2 – 8

The Pharma Data

December is bringing frost in the North and plenty of cold hard cash for these life sciences companies. . European venture capital firm Forbion rounded up $545 million for its fifth life sciences fund. Laying down a new track for RNA processing, Remix launched with $81 million in financing. Pear Therapeutics.

RNA 52
article thumbnail

Five Promising Treatment Areas in Early-Phase Drug Development in 2024

Alta Sciences

Five Promising Treatment Areas in Early-Phase Drug Development in 2024 aasimakopoulos Wed, 04/17/2024 - 15:52 Early-phase drug development is an ever-changing landscape, as emerging science leads to new promising areas of research for the treatment of human health issues. Tags Science and Health About Altasciences Weight 1

article thumbnail

A therapy candidate for fatal prion diseases turns off disease-causing gene

Broad Institute

By Greta Friar, Whitehead Institute June 27, 2024 Images of a mouse brain show the effect of a technology called CHARM in turning off the expression of a gene in the brain. CRISPRoff uses building blocks from CRISPR gene editing technology, including the guide protein Cas9 that directs the tool to the target gene. Online June 27, 2024.

Disease 142